ReviewClinical and translational allergy2017
Looking forward to new targeted treatments for chronic spontaneous urticaria.
Review in Clinical and translational allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 63 citations in OpenAlex.
- Beyond Antihistamines: How Biologic and Small-Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults.Clinical drug investigation · 2025Review
- Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China.Cost effectiveness and resource allocation : C/E · 2025Article
- Article
- Cytokine Profiles of Chronic Urticaria Patients and The Effect of Omalizumab Treatment.Dermatology practical & conceptual · 2023Article
- Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review.Clinical reviews in allergy & immunology · 2022Review
- Exhaled Nitric Oxide Level in Pharynx Angioedema.Journal of clinical medicine · 2022Article
- A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.Advances in experimental medicine and biology · 2021Article
- Chronic urticaria and thyroid pathology.The World Allergy Organization journal · 2020Article
- The Emerging Role of IL-17 in the Immune-Pathogenesis of Chronic Spontaneous Urticaria.ImmunoTargets and therapy · 2020Review
- Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications.Journal of asthma and allergy · 2019Article
- Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.Pediatric allergy, immunology, and pulmonology · 2018Review
- Urticaria and Angioedema: an Update on Classification and Pathogenesis.Clinical reviews in allergy & immunology · 2018Review
- Focus on the role of substance P in chronic urticaria.Clinical and molecular allergy : CMA · 2018Review
- Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease?Mediators of inflammation · 2017Review
- Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria.Clinical and translational allergy · 2017Article
- Biologicals in Treatment of Chronic Urticaria: A Narrative Review.Indian dermatology online journalReview
- Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?Anais brasileiros de dermatologiaArticle
- Increased Plasma Levels of S100A8, S100A9, and S100A12 in Chronic Spontaneous Urticaria.Indian journal of dermatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include rituximab and tumour necrosis factor inhibitors. Ligelizumab (anti-IgE), canakinumab (anti-IL-1), AZD1981 (a PGD2 receptor antagonist) and GSK 2646264 (a selective Syk inhibitor) are currently in clinical trials for CSU. Examples of drugs that could target potential pathophysiological targets in CSU include substance P antagonists, designed ankyrin repeat proteins, C5a/C5a receptor inhibitors, anti-IL-4, anti-IL-5 and anti-IL-13 and drugs that target inhibitory mast cell receptors. Other mediators and receptors of likely pathogenic relevance should be explored in skin profiling and functional proof of concept studies. The exploration of novel therapeutic targets for their role and relevance in CSU should help to achieve a better understanding of its etiopathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.